Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.59 |
| ▸ | BACE1 | P56817 | 6/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761451 | 0.93 | ACHE (0.67) | ACHEBACE1PDE10APDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL4760523 | 0.92 | ACHE (0.66) | ACHEBACE1PDE10APDE3BPDE3A | |
| SCHEMBL4399140 | 0.90 | HTR7 (0.64) | ACHEBACE1PDE10APDE3BPDE3A | |
| SCHEMBL4762801 | 0.86 | ACHE (0.62) | ACHEBACE1PDE10APDE3BPDE3A | |
| SCHEMBL4405043 | 0.84 | ACHE (0.52) | ACHEBACE1PDE10AMAPK1PDE3B | |
| SCHEMBL14407961 | 0.82 | HTR7 (0.68) | ACHEBACE1PDE10APDE3AEGFR | |
| SCHEMBL4406170 | 0.81 | ACHE (0.58) | ACHEBACE1PDE10APDE3BPDE3A | |
| SCHEMBL4761903 | 0.81 | ACHE (0.55) | ACHEBACE1PDE10APDE3BPDE3A | |
| SCHEMBL4760279 | 0.81 | ACHE (0.55) | ACHEBACE1PDE10APDE3BPDE3A | |
| SCHEMBL4718402 | 0.81 | ACHE (0.55) | ACHEBACE1PDE10AMAPK1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940819-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | claimed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | claimed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | claimed |
| EP-1723134-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | Pfizer Products Incorporated (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | claimed |
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2005-08-18 | — | — | US | claimed |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| EP-1940819-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| EP-1755611-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1723134-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | Pfizer Products Incorporated (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005120514-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PDE5A, PDE3A, PDE3B | ACHE 20/4885BACE1 570/4885PDE10A 13/4885 |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | ACHE 66/4885BACE1 707/4885PDE10A 3/4885 |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PDE5A, PDE12, PDE2A | ACHE 86/4885BACE1 874/4885PDE10A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.